Pharmaceutical / Drug Definition :
Stimulates alpha-adrenergic receptors, causing intracranial and peripheral vasoconstriction. Also activates 5-hydroxytryptamine-1D receptors to inhibit release of proinflammatory neuropeptides.
FDA Label Requirements and Exceptions
Dihydroergotamine Mesylate
FDA Import Information
Dihydroergotamine Mesylate
FDA Detentions
Dihydroergotamine Mesylate (Dihydroergotamine Mesylate Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Dihydroergotamine Mesylate (Dihydroergotamine Mesylate Suppliers)
- Processors Dihydroergotamine Mesylate
- Repackers Dihydroergotamine Mesylate
- Relabelers Dihydroergotamine Mesylate
- Exporters Dihydroergotamine Mesylate
- Importers Dihydroergotamine Mesylate
For more information about Dihydroergotamine Mesylate, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.
